The effects of subchronic administration of the 5-HT1A receptor agonist buspirone and its new complex with glycyrrhizic acid (GA) to mice at different stages of development of an anxious-depressive state induced by social stress were studied. On the background of stress (during formation of the pathology), only the complex had protective actions, preventing the development of anxiety and retaining a high level of communicativeness among the animals. At the stage at which the anxious-depressive state had formed, buspirone and its complex with GA decreased motor activity in the mice, this effect of the complex being less marked. This article discusses the possible mechanisms of action of these compounds on the background of changes in the sensitivity of brain 5-HT1A receptors due to the formation of the pathological state in mice due to social stress. Despite the different actions of substances and depending on the extent of development of the anxious-depressive state, the new buspirone/GA complex had some advantage over buspirone
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
D. F. Avgustinovich, O. V. Alekseenko, I. V. Bakshtanovskaya, et al., “Dynamic changes in brain serotoninergic and dopaminergic activity during the development of depression: an experimental study,” Usp. Fiziol. Nauk., 35, No. 4, 19–40 (2004).
D. F. Avgustinovich and G. B. Vishnivestskaya, “Effects of chronic administration of buspirone to female mice in prolonged psychoemotional conditions,” Ros. Fiziol. Zh., 97, No. 2, 189–202 (2011).
D. F. Avgustinovich and K. Fomina, “Effects of buspirone on the behavior of female mice in a social discomfort model,” Ros. Fiziol. Zh., 98, No. 6, 693–705 (2012).
A. V. Dushkin, T. G. Tolstikova, G. A. Tolstikov, and E. S. Meteleva, Patent No. 233710 RF, “A water-soluble medicinal composition and the method of preparation” (2008).
T. G. Tolstikova, A. G. Tolstikov, and G. A. Tolstikov, Plant-Derived Medicines, Geo, Novosibirsk (2010).
J. T. Asper and L. A. Allen, “Buspirone: future directions,” J. Clin. Psychopharmacol., 19, No. 1, 86–93 (1999).
P. L. Blier and N. M. Ward, “Is there a role for 5-HT1A agonists in the treatment of depression?” Biol. Psychiatry, 53, No. 3, 193–203 (2003).
W. C. Drevets, M. E. Thase, E. L. Moses-Kolko, et al., “Serotonin-1A receptor imaging in recurrent depression: replication and literature review,” Nucl. Med. Biol., 34, No. 7, 865–877 (2007).
K. L. Goa and A. Ward, “Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic,” Drugs, 32, No. 2, 114–129 (1986).
H. L. Goldberg and R. J. Finnerty, “The comparative efficacy of buspirone and diazepam in the treatment of anxiety,” Am. J. Psychiatry, 136, No. 9, 1184–1187 (1979).
G. Griebel and A. Holmes, “50 years of hurdles and hope in anxiolytic drug discovery,” Nat. Rev. Drug Discov., 12, No. 9, 667–687 (2013).
L. K. Heiser, H. M. Chu, T. J. Brennan, et al., “Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice,” Proc. Natl. Acad. Sci. USA, 95, No. 25, 15,049–15,054 (1998).
A. Holmes, D. L. Murphy, and J. N. Crawley, “Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression,” Biol. Psychiatry, 54, No. 10, 953–959 (2003).
R. T. Joffe and D. R. Schuller, “An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression,” J. Clin. Psychiatry, 54, No. 7, 269–271 (1993).
R. C. Kessler, S. Aguilar-Gaxiola, J. Alonso, et al., “The WHO World Mental Health (WMH) Surveys,” Psychiatrie (Stuttgart), 6, No. 1, 5–9 (2009).
N. N. Kudryavtseva, “Experience of defeats decreases the behavioral reactivity to conspecifi c in partition test,” Behav. Proc., 32, No. 3, 297–304 (1994).
N. N. Kudryavtseva and D. F. Avgustinovich, “Behavioral and physiological markers of experimental Depression Induced by Social Conflicts (DISC),” Aggr. Behav., 214, No. 4, 271–286 (1998).
N. N. Kudryavtseva, I. V. Bakshtanovskaya, and L. A. Koryakina, “Social model of depression in mice of C57BL/6J strain,” Pharmacol. Biochem. Behav., 38, No. 2, 315–320 (1991).
R. R. Lanzenberger, M. Mitterhouser, C. Spindelegger, et al., “Reduced serotonin-1A receptor binding in social anxiety disorder,” Biol. Psychiatry, 61, No. 9, 1081–1089 (2007).
Q. Li, A. Holmes, L. Ma, et al., “Medial hypothalamic 5-hydroxytryptamine (5-HT)1A receptors regulate neuroendocrine responses to stress and exploratory locomotor activity: application of recombinant adenovirus containing 5-HT 1 A sequences,” J. Neurosci., 24, No. 48, 10,868–10,877 (2004).
C. Loane and M. Politis, “Buspirone: what is it all about?” Brain Res., 1461, No. 1, 111–118 (2012).
I. Lucki, “Behavioral studies of serotonin receptor agonists as antidepressant drugs,” J. Clin. Psychiatry, 52, Supplement, 24–31 (1991).
E. Majercsik, J. Haller, C. Leveleki, et al., “The effect of social factors on the anxiolytic efficacy of buspirone in male rats, male mice, and men,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, No. 8, 1187–1199 (2003).
W. T. McKinney and W. E. Bunney, “Animal model of depression. I. Review of evidence: implications for research,” Arch. Gen. Psychiatry, 21, No. 2, 240–248 (1969).
P. J. Mitchell and P. H. Redfern, “Animal models of depressive illness: the importance of chronic drug treatment,” Curr. Pharm. Des., 11, No. 2, 171–203 (2005).
A. Neumeister, E. Bain, A. C. Nugent, et al., “Reduced serotonin type 1A receptor binding in panic disorder,” J. Neurosci., 24, No. 3, 589–591 (2004).
R. D. Porsolt, M. Le Pichon, and M. Jalfre, “Depression: a new animal model sensitive to antidepressant treatments,” Nature, 266, No. 5604, 730–732 (1977).
L. Prut and C. Belzung, “The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review,” Eur. J. Pharmacol., 463, No. 1–3, 3–33 (2003).
R. J. Rodgers and J. C. Cole, “The elevated plus-maze: pharmacology, methodology and ethology,” in: Ethology and Psychophar macology, S. J. Cooper and C. A. Hendrie (eds.), John Wiley & Sons Ltd, Chichester (1994), pp. 9–44.
E. Shireen and D. J. Haleem, “Motor effects of buspirone: Relationship with dopamine and serotonin in the striatum,” J. Coll. Physicians Surg. Pak., 15, No. 12, 753–756 (2005).
G. E. Simon, M. Von Korff, M. Piccinelli, et al., “An international study of the relation between somatic symptoms and depression,” N. Engl. J. Med., 341, No. 18, 1329–1335 (1999).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 100, No. 7, pp. 808–819, July, 2014.
Rights and permissions
About this article
Cite this article
Fomina, M.K., Avgustinovich, D.F. & Tolstikova, T.G. Studies of the Effects of a Complex of Buspirone with Glycyrrhyzic Acid on the Behavior of Mice during Formation of an Anxious-Depressive State. Neurosci Behav Physi 46, 153–159 (2016). https://doi.org/10.1007/s11055-015-0212-7
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-015-0212-7